165 related articles for article (PubMed ID: 21804580)
1. The impact of mergers on pharmaceutical R&D.
LaMattina JL
Nat Rev Drug Discov; 2011 Aug; 10(8):559-60. PubMed ID: 21804580
[TBL] [Abstract][Full Text] [Related]
2. Research and development productivity map: visualization of industry status.
Shimura H; Masuda S; Kimura H
J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
[TBL] [Abstract][Full Text] [Related]
3. Mergers and innovation in the pharmaceutical industry.
Comanor WS; Scherer FM
J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
[TBL] [Abstract][Full Text] [Related]
4. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
Shimura H; Masuda S; Kimura H
Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
[TBL] [Abstract][Full Text] [Related]
5. The case for entrepreneurship in R&D in the pharmaceutical industry.
Douglas FL; Narayanan VK; Mitchell L; Litan RE
Nat Rev Drug Discov; 2010 Sep; 9(9):683-9. PubMed ID: 20725093
[TBL] [Abstract][Full Text] [Related]
6. Micro factors bringing the pharmaceutical industry to a seismic shaking a qualitative research.
Dierks RML; Bruyère O; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):267-274. PubMed ID: 28679327
[TBL] [Abstract][Full Text] [Related]
7. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
Forster SP; Stegmaier J; Spycher R; Seeger S
Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
[TBL] [Abstract][Full Text] [Related]
8. Effect of mergers and acquisitions on drug discovery: perspective from a case study of a Japanese pharmaceutical company.
Shibayama S; Tanikawa K; Fujimoto R; Kimura H
Drug Discov Today; 2008 Jan; 13(1-2):86-93. PubMed ID: 18190869
[TBL] [Abstract][Full Text] [Related]
9. Mega-mergers in the pharmaceutical industry. In whose interests?
Po AL
Pharmacoeconomics; 1998 Oct; 14(4):349-55. PubMed ID: 10344903
[TBL] [Abstract][Full Text] [Related]
10. Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry.
Dierks RML; Bruyère O; Reginster JY
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):147-160. PubMed ID: 29243501
[TBL] [Abstract][Full Text] [Related]
11. Do large mergers increase or decrease the productivity of pharmaceutical R&D?
Ringel MS; Choy MK
Drug Discov Today; 2017 Dec; 22(12):1749-1753. PubMed ID: 28646641
[TBL] [Abstract][Full Text] [Related]
12. Reviving an R&D pipeline: a step change in the Phase II success rate.
Wu SS; Fernando K; Allerton C; Jansen KU; Vincent MS; Dolsten M
Drug Discov Today; 2021 Feb; 26(2):308-314. PubMed ID: 33129994
[TBL] [Abstract][Full Text] [Related]
13. Aspects of research and development contract terms in the bio/pharmaceutical sector.
Banerjee T
Adv Health Econ Health Serv Res; 2012; 23():1-33. PubMed ID: 23156659
[TBL] [Abstract][Full Text] [Related]
14. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
Schuhmacher A; Brieke C; Gassmann O; Hinder M; Hartl D
Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
[TBL] [Abstract][Full Text] [Related]
15. Models for open innovation in the pharmaceutical industry.
Schuhmacher A; Germann PG; Trill H; Gassmann O
Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
[TBL] [Abstract][Full Text] [Related]
16. 2016 in review: FDA approvals of new molecular entities.
Griesenauer RH; Kinch MS
Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
[TBL] [Abstract][Full Text] [Related]
17. Increase in R&D openness to tackle disease in the developing world.
Parks L
Future Med Chem; 2012 Dec; 4(18):2237. PubMed ID: 23234547
[No Abstract] [Full Text] [Related]
18. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
19. Foundation-industry relationships--a new business model joint-venture philanthropy in therapy development.
Bartek RJ
Curr Top Med Chem; 2014; 14(3):313-8. PubMed ID: 24283968
[TBL] [Abstract][Full Text] [Related]
20. Drug development risk and the cost of capital.
Baras AI; Baras AS; Schulman KA
Nat Rev Drug Discov; 2012 Apr; 11(5):347-8. PubMed ID: 22498751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
